The Future Viability of 105(a) Injunctions Following the Supreme Court's Decision In 'Purdue Pharma'
Until now, a successful reorganization assumed the debtor could confirm a plan with nondebtor releases and injunctions based on less than full creditor consensus. Now that nonconsensual releases in Chapter 11 plans are no longer permitted, will debtors have a more difficult time obtaining a 105(a) injunction?Intel Again Accused of Misleading Investors on Foundry Finances
It's the second case bringing similar allegations against Intel in the Delaware court.Chancery Court Opinion in 'Centrella v. Avantor': A Continuation of Expanding Advancement Rights
The recent decision by Delaware Vice Chancellor Nathan Cook in Centrella v. Avantor Inc. continues a notable trend in Delaware jurisprudence, emphasizing the broad application of advancement rights.K&L Gates Expands Corporate Practice With Wilmington Partner Addition
Global law firm K&L Gates welcomed Kelly Terribile as a partner in its corporate practice in Delaware.Kirkland Steps Aside While Big Law Bankruptcy Peers Keep Filing in Houston
Kirkland's favorite bankruptcy destination appears off-limits for now, but competing firms haven't shied from the Southern District of Texas following a 2023 scandal.Barnes & Thornburg Welcomes New Manager in Delaware
Barnes & Thornburg announced that the firm has added environmental, litigation, labor and employment, corporate, real estate, and government services and finance attorneys and legal professionals offices, including Conor McGuffin as manager of unclaimed property in the Delaware office.Potential Bankruptcy Relief for Individual Owner of Cannabis Businesses?
The court found that the simple administration of certain ownership interests of retail cannabis dispensaries "is not in and of itself necessarily equivalent to administering marijuana assets." And, as such, a Chapter 7 trustee could administer and monetize these ownership interests without violating the law.Tesla Shareholders Move to Consolidate Cases Over Musk's Focus on X, AI
If the motion is granted, the court would go from juggling seven cases against Tesla and Elon Musk to five.'Monopoly Prices'?: Big Pharma Co. Amgen Accused of Anticompetitive Conduct
"A 50-mg dose of Enbrel now costs patients $7,401.83 per month: 643% more than it cost when launched in 1998," according to the allegations in the antitrust class action filed against Enbrel manufacturer Amgen Inc.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250